ClinicalTrials.gg
Active, not recruitingNCT07215559Updated Oct 9, 2026

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

A Phase 2 interventional study of Macupatide and Eloralintide in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Active, not recruiting at 42 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Updated Oct 9, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing eloralintide in Obesity — 13 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.

Planned enrollment
13th of 22
200 · median 315
Started
2025
with 3 others
Phase 2
5 of 22
2 open now
Primary completion
2027-03
later than 1 of 14 live
Registered
9th of 22
by date
Lead sponsor
22 of 22
Eli Lilly and Company

Among the 22 studies testing eloralintide in Obesity, this one is the 13th largest by planned enrollment, is one of 4 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 1 of the 14 other live ones, and was the 9th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About eloralintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing eloralintide in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

03

Conditions studied

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2

Keywords

  • GIP
  • Amylin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes
  • Have an ≥7.5% to ≤10.5% at screening
  • Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening

    • Diet and exercise
    • Stable dose of metformin
    • Sodium-glucose cotransporter-2 (SGLT2) inhibitor
  • Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
  • Have a of 27 or greater at screening

Exclusion criteria

Exclusion Criteria:

  • Have any form of diabetes other than type 2 diabetes
  • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
  • Have any of the following cardiovascular conditions within 3 months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure
  • Have a history of an active or untreated or are in remission from a malignancy for less than 5 years, exceptions include

    • basal or squamous cell skin cancer
    • in situ carcinomas of the cervix, or
    • in situ prostate cancer
  • Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:

    • amylin RA
    • dual amylin and calcitonin RA
    • glucagon-like peptide-1 receptor (GLP-1) RA
    • glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
    • GLP-1/glucagon (GCG) RAs, or
    • GIP/GLP-1/GCG RAs
  • Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
  • Have used insulin for diabetic control within the prior year (short term use in certain situations allowed
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Macupatide (Macupatide + Eloralintide Placebo)

    Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC

    Drug: Macupatide · Drug: Eloralintide Placebo

  • Experimental
    Eloralintide (Elorlintide + Macupatide Placebo)

    Participants will be administered eloralintide SC and macupatide placebo SC

    Drug: Eloralintide · Drug: Macupatide Placebo

  • Experimental
    Macupatide + Eloralintide

    Participants will be administered eloralintide SC and macupatide SC

    Drug: Macupatide · Drug: Eloralintide

  • Placebo comparator
    Placebo (Macupatide Placebo + Elorlintide Placebo)

    Participants will be administered eloralintide placebo SC and macupatide placebo SC

    Drug: Macupatide Placebo · Drug: Eloralintide Placebo

Interventions

  • Administered SC

    Also known as: LY3532226

  • Administered SC

    Also known as: LY3841136

  • DrugMacupatide Placebo

    Administered SC

  • DrugEloralintide Placebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 32

Secondary outcomes

  1. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 32

  2. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 32

  3. Change from Baseline in Fasting Glucose

    Time frame: Baseline, Week 32

07

Study locations

42 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 17 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2025
First posted
Oct 10, 2025
StartActual
Oct 16, 2025
Primary completionEst.
Mar 2027
CompletionEst.
May 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07215559
Responsible party
Sponsor
First posted
Oct 10, 2025
Start date
Oct 16, 2025
Primary completion
Mar 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Macupatide · Eloralintide

Start the discussion